SEC Form 4 · accession 0001209191-19-012803
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Leber
Officer — Chief Communication Officer
Period of report
Feb 20, 2019
Accepted (ET)
Feb 22, 2019 · 8:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 20, 2019 | M | 18,750 | $17.18 | A | 39,599 | D | |
| Common StockF2,F3,F4,F1 | Feb 20, 2019 | S | 15,479 | $82.7382 | D | 24,120 | D | |
| Common StockF2,F3,F5,F1 | Feb 20, 2019 | S | 3,271 | $83.4971 | D | 20,849 | D | |
| Common StockF1 | Feb 21, 2019 | M | 1,817 | $22.98 | A | 22,666 | D | |
| Common StockF2,F3,F6,F1 | Feb 21, 2019 | S | 1,067 | $85.4661 | D | 21,599 | D | |
| Common StockF2,F3,F7,F1 | Feb 21, 2019 | S | 750 | $86.3951 | D | 20,849 | D | |
| Common StockF2,F8,F1 | Feb 21, 2019 | S | 3,817 | $77.5706 | D | 17,032 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F9 | $17.18 | Feb 20, 2019 | M | 18,750 | D | — | Feb 18, 2020 | Common Stock | 18,750 | 0 | D |
| Employee Stock Option (right to buy)F10 | $22.98 | Feb 21, 2019 | M | 1,817 | D | — | Jan 27, 2021 | Common Stock | 1,817 | 13,183 | D |
Explanation of responses
- F1Includes an aggregate of 13,201 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F10The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 14, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $82.17 to $83.16.
- F5Represents weighted average sale price. Actual sale prices ranged from $83.18 to $83.70.
- F6Represents weighted average sale price. Actual sale prices ranged from $85.11 to $86.06.
- F7Represents weighted average sale price. Actual sale prices ranged from $86.15 to $86.55.
- F8Represents actual sale price.
- F9The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.